To conduct network meta-analysis (NMA) of clinical efficacy and safety of singledose antiviral drugs, grouped by dosage, in treatment of influenza. Systematic retrievals were conducted in databases, including Pubmed, Embase, Web of Science, the Cochrane Register of Clinical Trials and from the website ClinicalTrials.gov, for clinical trials recorded between the interception of the databases and March 31, 2021. Randomized controlled trials (RCTs) of influenza treatment in which singledose antiviral drugs were administered were selected according to preset inclusion and exclusion criteria by two researchers who screened the literature independently from each other. The quality of the included studies was assessed using the Cochrane bias risk assessment tool. Software such as Stata 16.0 and Review Manager 5.3 was adopted for statistical analysis. Pairwise meta-analysis and NMA were carried out under the random-effects model. For both binary and continuous variables, odds ratio (OR), mean difference (MD) and their 95% confidence intervals (CI) were used to rank treatment efficiencies and analyze the differences. A total of 12 RCTs involving 7296 participants were included in the analysis. According to the

Purpose: To compare the effectiveness and safety of marketed oral drugs for overactive bladder based on a systematic review and network meta-analysis approach. Methods: Pubmed, Embase, Web of Science, and the Cochrane Register of Clinical Trials databases were systematically searched. The search time frame was from database creation to June 2, 2022. Randomized controlled double-blind trials of oral medication for overactive bladder were screened against the protocol's entry criteria. Trials were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Stata 16.0 software. Result: A total of 60 randomized controlled double-blind clinical trials were included involving 50,333 subjects. Solifenacin 10mg was the most effective in mean daily micturitions and incontinence episodes, solifenacin 5/10mg in mean daily urinary urgency episodes and nocturia episodes, fesoterodine 8mg in urgency incontinence episodes/d and oxybutynin 5mg in voided volume/micturition. In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of dry mouth, fesoterodine 4mg, ER-oxybutynin 10mg, tolterodine 2mg, and vibegron in the incidence of constipation. Compared to placebo, imidafenacin 0.1mg showed a significantly increased incidence in hypertension, solifenacin 10mg in urinary tract infection, fesoterodine 4/8mg and darifenacin 15mg in headache. Conclusion: Solifenacin showed better efficacy. For safety, most anticholinergic drugs were more likely to cause dry mouth and constipation, lower doses were better tolerated. The choice of drugs should be tailored to the patient's specific situation to find the best balance between efficacy and safety.

Purpose To compare the effectiveness and safety of marketed oral drugs for the treatment of overactive bladder. Methods Pubmed, Embase, Web of Science, and The Cochrane Register of Clinical Trials databases were systematically searched. The search time frame was from database creation to June 2, 2022, and randomized controlled double-blind trials of oral drugs for overactive bladder were screened. Trials were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Stata 16.0 to compare and rank differences in effectiveness and safety. Result A total of 60 randomized controlled double-blind trials were included. Solifenacin 10mg was the most effective in micturitions and incontinence episodes, solifenacin 5/10mg in urgency and nocturia, fesoterodine 8mg in urgency incontinence and oxybutynin 5mg in voided volume/micturition. For safety, mirabegron, vibegron, solifenacin 5mg, extended-release tolterodine 4mg and extended-release oxybutynin 10mg all showed a better incidence of dry mouth; Compared to placebo, only imidafenacin 0.1mg, showed a significantly increased incidence in hypertension, solifenacin 10mg in urinary tract infection, fesoterodine 4/8mg and controlled release darifenacin 15mg in headache. Conclusion Solifenacin showed better efficacy. For safety, most anticholinergics were more likely to cause dry mouth and constipation, while β-adrenergic agonists showed an increased incidence of nasopharyngitis. The choice of therapeutic agent should be tailored to the patient's situation in order to find the best balance between efficacy and safety.